| Bioactivity | ErSO-DFP is an anticipatory unfolded protein response (a-UPR) activator. ErSO-DFP has enhanced selectivity for estrogen receptor alpha-positive (ERα+) cancer cells with a wider selectivity window than ErSO.ErSO-DFP displays antitumor activity and leads to profound regression of MCF-7 tumors in mice model[1]. | ||||||||||||
| Name | ErSO-DFP | ||||||||||||
| CAS | 2768139-76-8 | ||||||||||||
| Formula | C20H17F5N2O2 | ||||||||||||
| Molar Mass | 412.35 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Matthew W Boudreau, et al. Activators of the Anticipatory Unfolded Protein Response with Enhanced Selectivity for Estrogen Receptor Positive Breast Cancer. J Med Chem. 2022 Mar 10;65(5):3894-3912. |
ErSO-DFP
CAS: 2768139-76-8 F: C20H17F5N2O2 W: 412.35
ErSO-DFP is an anticipatory unfolded protein response (a-UPR) activator. ErSO-DFP has enhanced selectivity for estrogen
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.